OBJECTIVE: Age adjusted incidence rate for uterine cancers in Norway has increased over last three decades from 12.2/100.000 (1981-90) to 16.0 (2001-2010). Corresponding 5-year survival increased nationally from 76.3% to 83.3%. METHODS: We wanted to investigate how changes in therapeutic strategies during a 30-year period are reflected in survival changes through careful characterization of a population-based series of 1077 endometrial carcinoma patients from Hordaland County, Norway. RESULTS: In concordance with increase in endometrial cancer nationally, the number of patients treated from Hordaland County rose from 286 (1981-1990) through 307 (1991-2000) to 484 (2001-2010). Main treatment changes included increase in routine pelvic lymphadenectomy from 0% through 9% to 77%, adjuvant chemotherapy from 0% through 3% to 9% and a dramatic reduction in adjuvant radiotherapy from 75% through 48% to 12% (all P<0.001). Body mass index increased significantly during this 30-year period, as did the 5-year disease-specific survival: from 75.8 through 80.2 to 86.9% (P=0.002) and overall survival from 67.8 through 71.7 to 77.8% (P=0.03). CONCLUSION: Improved overall and disease specific survival for endometrial carcinoma patients over the last 30 years is demonstrated in a population-based setting. Increasing BMI among patients and a change in treatment strategy with reduction in adjuvant radiotherapy and more extensive surgery is demonstrated for the same period.
OBJECTIVE: Age adjusted incidence rate for uterine cancers in Norway has increased over last three decades from 12.2/100.000 (1981-90) to 16.0 (2001-2010). Corresponding 5-year survival increased nationally from 76.3% to 83.3%. METHODS: We wanted to investigate how changes in therapeutic strategies during a 30-year period are reflected in survival changes through careful characterization of a population-based series of 1077 endometrial carcinomapatients from Hordaland County, Norway. RESULTS: In concordance with increase in endometrial cancer nationally, the number of patients treated from Hordaland County rose from 286 (1981-1990) through 307 (1991-2000) to 484 (2001-2010). Main treatment changes included increase in routine pelvic lymphadenectomy from 0% through 9% to 77%, adjuvant chemotherapy from 0% through 3% to 9% and a dramatic reduction in adjuvant radiotherapy from 75% through 48% to 12% (all P<0.001). Body mass index increased significantly during this 30-year period, as did the 5-year disease-specific survival: from 75.8 through 80.2 to 86.9% (P=0.002) and overall survival from 67.8 through 71.7 to 77.8% (P=0.03). CONCLUSION: Improved overall and disease specific survival for endometrial carcinomapatients over the last 30 years is demonstrated in a population-based setting. Increasing BMI among patients and a change in treatment strategy with reduction in adjuvant radiotherapy and more extensive surgery is demonstrated for the same period.
Authors: T S Njølstad; J Trovik; T S Hveem; M L Kjæreng; W Kildal; M Pradhan; J Marcickiewicz; S Tingulstad; A C Staff; H K Haugland; R Eraker; K Oddenes; J A Rokne; J Tjugum; M S Lode; F Amant; H M Werner; H B Salvesen; H E Danielsen Journal: Br J Cancer Date: 2015-04-21 Impact factor: 7.640
Authors: Tormund S Njølstad; Henrica M Werner; Janusz Marcickiewicz; Solveig Tingulstad; Anne C Staff; Klaus Oddenes; Line Bjørge; Marie E Engh; Kathrine Woie; Jostein Tjugum; Margaret S Lode; Frederic Amant; Helga B Salvesen; Jone Trovik Journal: PLoS One Date: 2017-08-03 Impact factor: 3.240
Authors: Karen Klepsland Mauland; Elisabeth Wik; Erling A Hoivik; Kanthida Kusonmano; Mari Kyllesø Halle; Anna Berg; Hans Kristian Haugland; Anne Margrete Øyan; Karl-Henning Kalland; Ingunn Marie Stefansson; Lars A Akslen; Camilla Krakstad; Jone Trovik; Henrica Maria Johanna Werner; Helga Birgitte Salvesen Journal: Oncotarget Date: 2017-02-07
Authors: Henrica M J Werner; Jone Trovik; Mari K Halle; Elisabeth Wik; Lars A Akslen; Even Birkeland; Therese Bredholt; Ingvild L Tangen; Camilla Krakstad; Helga B Salvesen Journal: PLoS One Date: 2014-02-25 Impact factor: 3.240